Clinical Trial Update: An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia [Phase 3]

View source ↗

Summary

An open-label Phase 3 study of IV-Globulin SN Inj.10% for immune thrombocytopenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• IV-Globulin SN Inj.10% (intravenous immunoglobulin)

Snippet

Sponsor: Green Cross Corporation | Conditions: Immune Thrombocytopenia | Phase 3 | Status: COMPLETED